FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2249052646> ?p ?o ?g. }

• W2249052646 endingPage "4751" @default.
• W2249052646 startingPage "4751" @default.
• W2249052646 abstract "4751 Background It is unknown if high doses of Cox -2 inhibitors in cancer regimens have adverse renal effects. Concerns include acute renal failure (ARF), hyperkalemia (hyper K), proteinuria and hypertension. Methods 33 patients (pts) with HRPC and median (med) age of 74 years (56–95) were treated in 2 phase II trials (Kasimis and Zhong: Proc ASCO 2005 subm). All received high dose C 400 mg bid po for a med period of 4 months (M) (2–6); 25 received Docetaxel, and 8 received Epirubicin and Extramustine Phosphate. Chemistries, UA, and blood pressure (BP) were measured at baseline and every M. All ARF and hyper K episodes were evaluated by a nephrologist. Results Table shows that estimated glomerular filtration rate (e-GFR), creatinine (creat), K and BP did not change during C treatments at 1 and at the final M compared to baseline. Minor, clinically unimportant decreases in serum calcium and bicarbonate, and increases in chloride were noted. 7 mild and reversible episodes of ARF (>50% rise in creat) occurred in 6 pts during 142 Ms of treatment (1 episode/20 Ms) due to volume depletion in 3, obstruction in 2, sepsis in 1, and contrast in 1. C was not a major precipitating factor and 6 of 7 pts continued C after ARF without recurrences (1 pt withdrew after renal function improved). 3 pts had solitary episodes of mild hyper K (5.5–6.0 mmol/L); 1 pt with DM nephropathy receiving ACE had 3 episodes of hyper K, reaching 6.6 mmol/L. After ACE was stopped in 2 pts, hyper K never recurred. No pts developed increasing proteinuria. Conclusion High dose C was well tolerated. The incidence of ARF and hyper K was low, and causes were attributed to other factors. No differences in renal function (creat, e-GFR), K, and BP were noted during 142 Ms of C treatment compared to baseline, and no pts developed persistent proteinuria. No significant financial relationships to disclose." @default.
• W2249052646 created "2016-06-24" @default.
• W2249052646 creator A5002988792 @default.
• W2249052646 creator A5007441251 @default.
• W2249052646 creator A5013528660 @default.
• W2249052646 creator A5024293511 @default.
• W2249052646 creator A5053554847 @default.
• W2249052646 creator A5054507516 @default.
• W2249052646 creator A5059356287 @default.
• W2249052646 creator A5060580890 @default.
• W2249052646 creator A5079772081 @default.
• W2249052646 creator A5089071121 @default.
• W2249052646 date "2005-06-01" @default.
• W2249052646 modified "2023-09-27" @default.
• W2249052646 title "Renal effects of high dose celecoxib (C) during 2 phase II trials for hormone resistant prostate cancer (HRPC)" @default.
• W2249052646 doi "https://doi.org/10.1200/jco.2005.23.16_suppl.4751" @default.
• W2249052646 hasPublicationYear "2005" @default.
• W2249052646 type Work @default.
• W2249052646 sameAs 2249052646 @default.
• W2249052646 citedByCount "0" @default.
• W2249052646 crossrefType "journal-article" @default.
• W2249052646 hasAuthorship W2249052646A5002988792 @default.
• W2249052646 hasAuthorship W2249052646A5007441251 @default.
• W2249052646 hasAuthorship W2249052646A5013528660 @default.
• W2249052646 hasAuthorship W2249052646A5024293511 @default.
• W2249052646 hasAuthorship W2249052646A5053554847 @default.
• W2249052646 hasAuthorship W2249052646A5054507516 @default.
• W2249052646 hasAuthorship W2249052646A5059356287 @default.
• W2249052646 hasAuthorship W2249052646A5060580890 @default.
• W2249052646 hasAuthorship W2249052646A5079772081 @default.
• W2249052646 hasAuthorship W2249052646A5089071121 @default.
• W2249052646 hasConcept C121608353 @default.
• W2249052646 hasConcept C126322002 @default.
• W2249052646 hasConcept C126894567 @default.
• W2249052646 hasConcept C141071460 @default.
• W2249052646 hasConcept C159641895 @default.
• W2249052646 hasConcept C2780306776 @default.
• W2249052646 hasConcept C2780835546 @default.
• W2249052646 hasConcept C530470458 @default.
• W2249052646 hasConcept C54847362 @default.
• W2249052646 hasConcept C71924100 @default.
• W2249052646 hasConcept C90924648 @default.
• W2249052646 hasConceptScore W2249052646C121608353 @default.
• W2249052646 hasConceptScore W2249052646C126322002 @default.
• W2249052646 hasConceptScore W2249052646C126894567 @default.
• W2249052646 hasConceptScore W2249052646C141071460 @default.
• W2249052646 hasConceptScore W2249052646C159641895 @default.
• W2249052646 hasConceptScore W2249052646C2780306776 @default.
• W2249052646 hasConceptScore W2249052646C2780835546 @default.
• W2249052646 hasConceptScore W2249052646C530470458 @default.
• W2249052646 hasConceptScore W2249052646C54847362 @default.
• W2249052646 hasConceptScore W2249052646C71924100 @default.
• W2249052646 hasConceptScore W2249052646C90924648 @default.
• W2249052646 hasIssue "16_suppl" @default.
• W2249052646 hasLocation W22490526461 @default.
• W2249052646 hasOpenAccess W2249052646 @default.
• W2249052646 hasPrimaryLocation W22490526461 @default.
• W2249052646 hasRelatedWork W1544023406 @default.
• W2249052646 hasRelatedWork W1974905876 @default.
• W2249052646 hasRelatedWork W1996438731 @default.
• W2249052646 hasRelatedWork W2031351830 @default.
• W2249052646 hasRelatedWork W2040716934 @default.
• W2249052646 hasRelatedWork W2046899919 @default.
• W2249052646 hasRelatedWork W2093809063 @default.
• W2249052646 hasRelatedWork W2591704513 @default.
• W2249052646 hasRelatedWork W2949179284 @default.
• W2249052646 hasRelatedWork W393698729 @default.
• W2249052646 hasVolume "23" @default.
• W2249052646 isParatext "false" @default.
• W2249052646 isRetracted "false" @default.
• W2249052646 magId "2249052646" @default.
• W2249052646 workType "article" @default.